J 2014

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

KISSOVÁ, Jarmila; Alena BULIKOVÁ; Petra OVESNÁ; Ludmila BOURKOVÁ; Miroslav PENKA et al.

Základní údaje

Originální název

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

Vydání

International Journal of Hematology, Tokio, Springer Japan, 2014, 0925-5710

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Japonsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.918

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00077527

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

Mean platelet volume (MPV); Immature platelet fraction (IPF); BCR/ABL-negative myeloproliferative neoplasms (MPN); Thrombosis

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 24. 4. 2015 13:56, Soňa Böhmová

Anotace

V originále

BCR/ABL-negative myeloproliferative neo¬plasms (MPNs) are considered to be acquired thrombo-philic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complica-tions. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (1PF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P — 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.